Alzheimer's Disease Against A Cancer

Alzheimer's Disease Against A Cancer.
Although a chew over in 2012 suggested a cancer deaden could reverse the thinking and memory problems associated with Alzheimer's disease, three groups of researchers now conjecture they have been unable to duplicate those findings. The teams said their experimentation could have serious implications for patient safety since the drug involved in the study, bexarotene (Targretin), has unsmiling side effects, such as major blood-lipid abnormalities, pancreatitis, headaches, fatigue, weight gain, depression, nausea, vomiting, constipation and rash. "Anecdotally, we have all heard that physicians are treating their Alzheimer's patients with bexarotene, a cancer pharmaceutical with punitive side effects," said study co-author Robert Vassar, a professor of chamber and molecular biology at Northwestern University Feinberg School of Medicine, in Chicago.

This way should be ended immediately, given the failure of three independent research groups to replicate the plaque-lowering clobber of bexarotene. The US Food and Drug Administration approved bexarotene in 1999 to manage refractory cutaneous T-cell lymphoma. Once approved, however, the narcotize also was available by prescription for "off-label" uses.

The 2012 study suggested that bexarotene was able to speedily reverse the build-up of beta amyloid plaques in the brains of mice. The authors of the beginning study concluded that treatment with the drug might reverse the cognitive and memory problems associated with the maturing of Alzheimer's. Sangram Sisodia, a professor of neurosciences at the University of Chicago and a study co-author of the modern development research, admitted being skeptical about the initial findings.

"We were surprised and excited - even stunned - when we anything else saw these results presented at a small conference," Sisodia said in a University of Chicago Medical Center statement release. "The mechanism of action made some sense, but the insistence that they could reduce the areas of plaque by 50 percent within three days and by 75 percent in two weeks seemed too knockout to be true".

In attempting to duplicate the findings, the research teams found that they were to be realistic too good to be true. "We all went back to our labs and tried to confirm these promising findings. We repeated the approve experiments - a standard process in science. Combined results are really outstanding in this field.

None of us found anything like what they described in the 2012 paper". Researchers at the University of Chicago, Northwestern University, Massachusetts General Hospital, Washington University in St Louis and the University of Tubingen in Germany reported in the May 24, 2013 descendant of the logbook Science that they did not find any reduction in beta amyloid plaques during or after therapy with bexarotene in three different strains of mice. Bexarotene has never been tested on relatives as a treatment for Alzheimer's disease discover more here. Currently, there is no cure or effective treatment for the ongoing condition, which affects an estimated 5,3 million Americans.